At Abiomed's European headquarters in Aachen, Germany, Impella heart pumps have been developed and produced for more than 20 years to stabilize and recover the human heart. The single access procedure ...

J&J’s Abiomed and manufacturing partner Oscor warned of a bleeding risk from devices used to introduce catheters to the body.

Abiomed Inc.ABMD recently announced that its Impella 2.5 heart pump has received FDA Pre-Market Approval (PMA) for use in high risk percutaneous coronary intervention (PCI) procedures. Notably, ...

Impella 2.5 is the Only FDA-Approved Percutaneous Hemodynamic Support Device Determined to be Safe and Effective for the High Risk PCI Indication DANVERS, MA – Abiomed, Inc., a leading provider of ...

Over 3,000 U.S. Patients Have Received Higher Flow Impella CP DANVERS, Mass., (GLOBE NEWSWIRE) -- Abiomed, Inc., a leading provider of breakthrough heart support technologies, today reported that ...

A procedure for those with advanced heart failure is now available in the Wichita area. The procedure, which implants a small pump called the Impella device through a patient’s artery, was performed ...

The Heart Hospital of Northwest Texas Healthcare System has been recognized by Abiomed for its achievement of 200 Impella procedures, according to a news release. This life-changing procedure has ...

Abiomed was founded in 1981 with the bold mission to create the world's first artificial heart. While decades of hard work ultimately resulted in a regulatory thumbs-up for the company's AbioCor ...

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces the United States Food and Drug Administration (FDA) has approved the company's investigational device exemption application to start ...

AACHEN, Germany--(BUSINESS WIRE)--Following consultation with its notified body, MEDCERT GmbH, Abiomed is introducing the single access procedure with Impella CP introducer sheaths for the treatment ...